Krystal Biotech Reports Strong Q2 2026 Earnings

What happened

In Q2 2026, Krystal Biotech reported net income of US$54.77 million and EPS of US$1.85, up from US$38.33 million and US$1.33 a year earlier. First-half 2026 net income reached US$110.70 million. Vyjuvek received UK marketing authorization.

Why it matters

Strong earnings reinforce Vyjuvek's role in profitability, though analysts project lower revenue and earnings by 2029. The UK approval supports international expansion but highlights risks regarding reimbursement and pricing.